Effect of single nucleotide polymorphism in thrombin-activatable fibrinolysis inhibitor on the risk of diabetic macrovascular disease

Chenghong Zheng, Xiaochao Li, Caixia Kong, Shuhong Ke, Cong Peng, Tianpen Cui, Mingsong Gao, Yang Zhou, Wei Guo, Lianqi Huang, Robert B. Petersen, Kun Huang

Research output: Contribution to journalArticlepeer-review

Abstract

Hypofibrinolysis is commonly found in patients with diabetes mellitus and is associated with the increased risk for many diabetic complications. An important inhibitor of fibrinolysis, thrombin-activatable fibrinolysis inhibitor (TAFI), participates in hypofibrinolysis in diabetes mellitus and may be involved in diabetic macrovascular disease. The present study was designed to determine whether TAFI polymorphisms (505G/A and 1040C/T) and TAFI levels are correlated with the development of type 2 diabetes mellitus (T2DM) and macrovascular diseases (MVDs). A total of 249 clinical samples were collected, including 102 healthy individuals (H group), 44 T2DM patients without MVD (T group) and 103 T2DM patients with MVD (M group). The 505G/A polymorphism was equally represented in the three groups. In contrast, analysis of the 1040C/T polymorphism revealed a statistically lower percentage of the T allele in the M group than in the H group (P=0.014). This difference was due to decreased T/T homozygotes in the M groups compared with the H group (P=0.029). The antigen TAFI level was 31.72±13.64% in the H group, 62.56±18.77% in the T group (P<0.05, compared with the H group) and 63.70±15.76% in the M group (P<0.05, compared with the H group). As high plasma TAFI level is associated with the increasing risk of T2DM, it may thus serve as a potential marker for the diagnosis of T2DM.

Original languageEnglish
Pages (from-to)185-190
Number of pages6
JournalBlood Coagulation and Fibrinolysis
Volume26
Issue number2
DOIs
StatePublished - Mar 6 2015

Keywords

  • antigen
  • diabetic macrovascular disease
  • thrombin-activatable fibrinolysis inhibitor polymorphism
  • type 2 diabetes

Fingerprint

Dive into the research topics of 'Effect of single nucleotide polymorphism in thrombin-activatable fibrinolysis inhibitor on the risk of diabetic macrovascular disease'. Together they form a unique fingerprint.

Cite this